NASDAQ:UROVUrovant Sciences Stock Price, Forecast & News

$8.75

+0.08 (+0.92 %)

(As of 05/25/2020 04:00 PM ET)

Add

Compare

Today's Range

$8.65

Now: $8.75▼

$8.92

50-Day Range

$8.27

MA: $8.90▼

$9.59

52-Week Range

$6.55

Now: $8.75▼

$15.98

Volume60,628 shs

Average Volume42,915 shs

Market Capitalization$267.05 million

P/E RatioN/A

Dividend YieldN/A

Beta1.44

Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. The company was founded in 2016 and is based in London, the United Kingdom. Urovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
Urovant Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $28.50, Urovant Sciences has a potential upside of 225.7% from its current price of $8.75.
Amount of Analyst Coverage
Urovant Sciences has received no research coverage in the past 90 days.

2.1 Community Rank

Outperform Votes
Urovant Sciences has received 67 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Urovant Sciences has received 93 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Urovant Sciences has received 58.13% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Urovant Sciences and other stocks. Vote “Outperform” if you believe UROV will outperform the S&P 500 over the long term. Vote “Underperform” if you believe UROV will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Urovant Sciences does not currently pay a dividend.
Dividend Growth
Urovant Sciences does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Urovant Sciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 7.62% of the stock of Urovant Sciences is held by insiders.
Percentage Held by Institutions
Only 23.81% of the stock of Urovant Sciences is held by institutions.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Urovant Sciences are expected to decrease in the coming year, from ($4.42) to ($5.63) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Urovant Sciences is -2.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Urovant Sciences is -2.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Urovant Sciences has a P/B Ratio of 3.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.12 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:UROV

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.urovant.com

Phone44-20-7400-3347

Debt

Debt-to-Equity Ratio1.83

Current Ratio2.32

Quick Ratio2.32

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$2.47 per share

Price / Book3.54

Profitability

EPS (Most Recent Fiscal Year)($4.43)

Net Income$-111,350,000.00

Net MarginsN/A

Return on Equity-351.07%

Return on Assets-122.63%

Miscellaneous

Employees17

Outstanding Shares30,520,000

Market Cap$267.05 million

Next Earnings Date6/11/2020 (Estimated)

OptionableNot Optionable

Receive UROV News and Ratings via Email

Sign-up to receive the latest news and ratings for UROV and its competitors with MarketBeat's FREE daily newsletter.

Urovant Sciences (NASDAQ:UROV) Frequently Asked Questions

How has Urovant Sciences' stock been impacted by COVID-19 (Coronavirus)?

Urovant Sciences' stock was trading at $11.37 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, UROV stock has decreased by 23.0% and is now trading at $8.75. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Urovant Sciences?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Urovant Sciences in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Urovant Sciences.

When is Urovant Sciences' next earnings date?

Urovant Sciences is scheduled to release its next quarterly earnings announcement on Thursday, June 11th 2020. View our earnings forecast for Urovant Sciences.

How were Urovant Sciences' earnings last quarter?

Urovant Sciences Ltd (NASDAQ:UROV) announced its quarterly earnings data on Thursday, February, 13th. The company reported ($1.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.95) by $0.41. View Urovant Sciences' earnings history.

What price target have analysts set for UROV?

2 Wall Street analysts have issued 1-year price objectives for Urovant Sciences' stock. Their forecasts range from $24.00 to $33.00. On average, they expect Urovant Sciences' stock price to reach $28.50 in the next year. This suggests a possible upside of 225.7% from the stock's current price. View analysts' price targets for Urovant Sciences.

What are Wall Street analysts saying about Urovant Sciences stock?

Here are some recent quotes from research analysts about Urovant Sciences stock:

1. According to Zacks Investment Research, "Urovant Sciences Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing therapies for urologic conditions. The company's product candidate pipeline consists of vibegron, an oral, once-daily, small molecule beta-3 agonist being evaluated in an international pivotal Phase 3 clinical trial for the treatment of overactive bladder. hMaxi-K, is a novel gene therapy being developed for patients with overactive bladder who have failed oral pharmacological therapy. Urovant Sciences Ltd. is based in Floor London, United Kingdom. " (3/28/2020)
2. HC Wainwright analysts commented, "Valuation and financial considerations appear noteworthy. From our vantage point, DSP’s involvement could meaningfully reduce any future need for Urovant to access equity or debt markets for further capital to fund the launch of vibegron." (9/9/2019)

Has Urovant Sciences been receiving favorable news coverage?

Headlines about UROV stock have trended very positive on Monday, InfoTrie reports. The research group identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Urovant Sciences earned a media sentiment score of 4.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the immediate future. View the latest news aboutUrovant Sciences.

Who are some of Urovant Sciences' key competitors?

Some companies that are related to Urovant Sciences include Applied Therapeutics (APLT), Phibro Animal Health (PAHC), Odonate Therapeutics (ODT), BioXcel Therapeutics (BTAI), Stoke Therapeutics (STOK), NextCure (NXTC), Athenex (ATNX), ImmunoGen (IMGN), Rhythm Pharmaceuticals (RYTM), Endo International (ENDP), Amphastar Pharmaceuticals (AMPH), Cue Biopharma (CUE), Gossamer Bio (GOSS), Omeros (OMER) and Passage Bio (ORIC). View all competitors.

What other stocks do shareholders of Urovant Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Urovant Sciences investors own include Opko Health (OPK), Agile Therapeutics (AGRX), CytomX Therapeutics (CTMX), Viking Therapeutics (VKTX), Aldeyra Therapeutics (ALDX), Anavex Life Sciences (AVXL), Corbus Pharmaceuticals (CRBP), Flexion Therapeutics (FLXN), Gilead Sciences (GILD) and Myovant Sciences (MYOV).

Who are Urovant Sciences' key executives?

Urovant Sciences' management team includes the following people:

Mr. Keith A. Katkin, CEO & Director (Age 48)
Ms. Christine G. Ocampo, Chief Accounting Officer and Principal Financial & Accounting Officer (Age 47)
Mr. Michael E. McFadden, Chief Commercial Officer of USI (Age 52)
Dr. David Hovland, Sr. VP of Global Regulatory Affairs
Ms. Nori Ebersole, Sr. VP & Chief HR Officer of USI (Age 56)

When did Urovant Sciences IPO?

(UROV) raised $150 million in an initial public offering (IPO) on Thursday, September 27th 2018. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Jefferies and Cowen served as the underwriters for the IPO.

What is Urovant Sciences' stock symbol?

Urovant Sciences trades on the NASDAQ under the ticker symbol "UROV."

Who are Urovant Sciences' major shareholders?

Urovant Sciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Perceptive Advisors LLC (7.76%), Alyeska Investment Group L.P. (1.58%), BlackRock Inc. (1.00%), First Manhattan Co. (0.75%), Park West Asset Management LLC (0.73%) and Wildcat Capital Management LLC (0.31%). Company insiders that own Urovant Sciences stock include Andrew Lo, Chemical Co Ltd Sumitomo, Fund V Lp Qvt, Holdings Ltd Dexxon, Kevin Costello, Patrick Machado, Qvt Associates Gp Llc and Sciences Ltd Roivant. View institutional ownership trends for Urovant Sciences.

Which major investors are selling Urovant Sciences stock?

UROV stock was sold by a variety of institutional investors in the last quarter, including Park West Asset Management LLC, Wildcat Capital Management LLC, Perceptive Advisors LLC, LVW Advisors LLC, and First Trust Advisors LP. View insider buying and selling activity for Urovant Sciences.

Which major investors are buying Urovant Sciences stock?

UROV stock was acquired by a variety of institutional investors in the last quarter, including Alyeska Investment Group L.P., First Manhattan Co., BlackRock Inc., and Geode Capital Management LLC. Company insiders that have bought Urovant Sciences stock in the last two years include Andrew Lo, Chemical Co Ltd Sumitomo, Fund V Lp Qvt, Holdings Ltd Dexxon, Kevin Costello, Patrick Machado, Qvt Associates Gp Llc, and Sciences Ltd Roivant. View insider buying and selling activity for Urovant Sciences.

How do I buy shares of Urovant Sciences?

Shares of UROV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Urovant Sciences' stock price today?

One share of UROV stock can currently be purchased for approximately $8.75.

How big of a company is Urovant Sciences?

Urovant Sciences has a market capitalization of $267.05 million. The company earns $-111,350,000.00 in net income (profit) each year or ($4.43) on an earnings per share basis. Urovant Sciences employs 17 workers across the globe.

What is Urovant Sciences' official website?

The official website for Urovant Sciences is www.urovant.com.

How can I contact Urovant Sciences?

Urovant Sciences' mailing address is 11-12 ST. JAMES S SQUARE SUITE 1 3RD FLOOR, LONDON X0, SW1Y 4LB. The company can be reached via phone at 44-20-7400-3347 or via email at [email protected]

This page was last updated on 5/25/2020 by MarketBeat.com Staff